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compared eight oral antineoplastics (capecitabine, imatinib, lenalidomide, thalido-
mide, sunitinib, erlotinib, temozolomide, dasatinib) to a market basket of eight com-
monly utilized oral drugs (celecoxib, sitagliptin, rosuvastatin, fenoﬁbrate, ramipril, 
simvastatin, atorvastatin, amlodipine). We calculated the correlation coefﬁcient (r2) 
for the relationships between a drug’s average OPC and its TRx. RESULTS: Two of 
the eight cancer drugs (erlotinib and dasatinib) showed any remarkable correlations 
(r2  0.17 and 0.29, respectively) while the other six all had correlation coefﬁcients 
less than 0.10. Five of the market basket drugs had a correlation coefﬁcient greater 
than 0.10. Four of those had negative correlations between OPC and TRx: simvastatin 
(r2  0.71), sitagliptin (r2  0.64), amlodipine (r2  0.59), atorvastatin (r2  0.14). 
Interestingly, ramipril had a signiﬁcant positive correlation between OPC and TRx (r2 
 0.51). CONCLUSIONS: Antineoplastic utilization appears to be inelastic with 
respect to OPC ﬂuctuations vis-à-vis the chosen market basket. This observation may 
be a function of the severity of disease, the lack of treatment options or both. In con-
trast, changes in OPC for products in the general market basket, notably simvastin 
and sitagliptin, precipitated signiﬁcant changes in drug utilization. Broader treatment 
options and speciﬁcally generic competition may contribute to this ﬁnding. Further 
research is warranted to track these relationships in a prospective, multi-factorial 
manner in order to better infer a cause-effect relationship.
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OBJECTIVES: As an extension of our 2008 study, which demonstrated that clustering 
of oncology speciﬁc resources exceeded the spatial concentration pattern of health 
care services observed in Greece, we analyzed nation–wide data, in order to identify 
and highlight the cross-regional ﬂows of cancer patients to access adequate treatment. 
METHODS: Patient admission and discharge data from public hospitals for the period 
1999–2005 were collected on a regional basis from the National Statistical Service of 
Greece (NSS). Patients with a cancer diagnosis were grouped according to a) place of 
residence and b) place of treatment for the 11 regions of Greece. RESULTS: A signiﬁ-
cant ﬂow of patients was observed towards Attika, the largest urban center and capital 
of Greece, where the number of cancer patients treated exceeded the number of cancer 
patients residing in the region by 48.9%, per year, on average. The reverse pattern 
(negative ﬂow) was observed in Sterea, Ionian Islands, Aegean Islands, Thessaly and 
Thrace, the corresponding percentages being 76.2%, 63.3%, 45.2%, 37.3% and 
27.9%, respectively. For the remaining 5 regions the ﬂows did not exceed o 10%. 
A further analysis based on type of cancer for the Attika region revealed that the 
highest ﬂows, proportionally, according to diagnoses, were observed for melanoma, 
malignant and benign neoplasms of the uterus and Hodgkin’s disease, whereas the 
lowest for benign neoplasms of the skin, the urinary organs and the thyroid. CON-
CLUSIONS: Cross-regional ﬂows of cancer patients to access adequate cancer treat-
ment is in line with the geographical misdistribution of oncology-speciﬁc resources in 
favor of larger urban areas, especially Attika. A fair allocation of resources according 
to population distribution and cancer prevalence, as well as ongoing disease manage-
ment programs at the place of residence, could greatly contribute to improved access 
to oncology services and minimize the socioeconomic burden to patients and their 
carers.
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OBJECTIVES: The Japanese Cancer Control Act took effect in 2007. The objectives 
of the Cancer Control Act are to improve regional cancer care and promote a uni-
formly high level of cancer care nationwide. To achieve these goals, the Act speciﬁes 
that all 47 prefectural governments in Japan formulate cancer control programs 
(CCPs) by 2008. Our study aimed to systematically review the CCPs of 45 of Japan’s 
prefectural governments that were formulated by January 2009 and then compare 
them to the programs that have been established in the West. METHODS: Six areas 
of the CCPs of 45 of Japan’s prefectural governments were systematically reviewed: 
“prevention,” “treatment,” and “palliative care.” etc. Parameters assessed included 
whether the proportion of smokers was being investigated, whether the numbers of 
radiation therapy and chemotherapy specialists engaged in cancer therapy were 
known, and whether the number of palliative care beds was known (a total of 224 
parameters). RESULTS: The highest-rated plan overall received a score of 65.8, and 
the lowest a score of 35.3. Of the 45 plans, 21 (47%) established target values without 
actually determining the current proportion of minors who smoke, 25 (56%) did not 
investigate the numbers of specialists in cancer therapy. In addition, areas in which 
Japan is similar to the UK and the US, which operate CCPs on a national level, were 
clariﬁed. CONCLUSIONS: It was found that not a few of the programs rest on shaky 
foundations and are of questionable implementability. An international comparison 
revealed that Britain’s NHS Cancer Plan has achieved a reduction in the smoking rate 
and increased anticancer drug use, and the United States’ NCCCP has produced results 
by supporting the CCPs of virtually all 50 states, achievements that should serve as a 
model for Japan.
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OBJECTIVES: Cancer screening is essential component of national cancer control 
programmes. Screening programmes for breast, colorectal and cervical cancers are 
efﬁcacious in decreasing cancer mortality and are recommended by the EU Council 
to all member states. For screening to be effective, delivery as organized programme 
is highly recommended. Vital part of organized programme is performance monitoring 
employing data on all screening tests performed. In absence of dedicated data collec-
tion system, alternative ways of performance monitoring should be employed. Our 
objective is to demonstrate feasibility of performance monitoring using administrative 
data. METHODS: This was a cross-sectional study to ascertain coverage by cancer 
screening tests in Czech population in years 2000–2007. Administrative data from 
health insurance companies were collected by the National Reference Centre. Aggre-
gated data were collected on procedures associated with cancer screening programmes, 
in particular screening mammography, FOBT, and gynaecology preventive examina-
tion. RESULTS: Most reliable data from years 2006–2007 were used for coverage 
estimation. In the two-year period, 745,725 women aged 45–69 years (43.5 %) 
underwent mammography screening, compared to 754,147 records in dedicated breast 
cancer screening database. In the same period, 593,512 men and women aged over 
50 years (16.0 %) underwent colorectal cancer screening. In 2007, gynaecology pre-
ventive examination was attended by 1,083,256 women (40.9 % of population aged 
25–59 years). CONCLUSIONS: Performance monitoring using administrative data is 
feasible, which was demonstrated by ascertaining screening test coverage. Concor-
dance between administrative data and data in dedicated breast cancer screening 
database is excellent. Due to absence of actual data on population coverage in other 
screening programmes, administrative data is the only available and reliable source of 
information on access to programme by citizens in all regions. Future use of individual 
administrative data could help us to evaluate various other screening process compo-
nents associated with its effectiveness, safety and cost-effectiveness.
PCN154
ANTICANCER DRUG EXPENDITURE IN CATALONIA 2003–2007
Paladio Duran N1, Almazán Sáez C1, Prat Casanovas A2
1Catalan Agency of Health Technology Assessment and Research, Barcelona, Spain, 
2Department of Health. Catalan Government, Barcelona, Spain
OBJECTIVES: The cost of drugs for cancer treatment continues to increase, especially 
with the addition of monoclonal antibodies and other targeted therapies to standard 
cancer treatment regimens. The purpose of this study was to examine the pharmaceuti-
cal expenditure growth in anticancer drugs in Catalonia between 2003 and 2007. 
METHODS: Data from the Pharmaceutical Care and Complementary Beneﬁts data-
base from the Catalan Health Service was used. This database contains information 
on all drugs dispensed in the outpatient setting in public hospitals. Drug expenditure 
was not adjusted for inﬂation and results are expressed in nominal terms. RESULTS: 
From 2003 to 2007, total drug expenditure (TDE) grew at an average annual rate of 
13.4%. During this period mean average growth rate for total anticancer drug expen-
diture (TACDE) was 46.1% increasing from 24,8 million Euros in 2003 to a111.6 
million in 2007. TACDE as percentage of TDE increased over the 5-year period from 
9% in 2003 to 22.6% in 2007. Considerable variation in growth of TACDE was 
observed across regions and hospitals. Six drugs (trastuzumab, imatinib, docetaxel, 
oxaliplatin, rituximab and paclitaxel) accounted for 67% of TACDE. The number of 
patients receiving anticancer drugs and the number of dispensed drugs increased by 
29,13% and 34,2%, respectively. Per patient anticancer drug expenditure increased 
from a3.896/patient in 2003 and a6.220/patient in 2007. Information in diagnosis 
was not available and analyses per type of cancer could not be performed. CONCLU-
SIONS: Anticancer drug expenditure in the outpatient setting has been increasingly 
growing during the study period. Both the volume of drug use and the entry of new 
drugs (typically introduced to the market at higher prices) seem to be explanatory 
factors determining drug spending trends in Catalonia. A more comprehensive 
approach to the use of anticancer drugs by type of cancer is of high importance.
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OBJECTIVES: To analyse key differences between the recently negotiated Pharma-
ceutical Price Regulation Scheme (PPRS) and previous schemes. Understanding the 
implications of these changes is important for the pharmaceutical industry and pricing 
and reimbursement (P&R) activities, particularly when considering the application of 
risk-sharing. METHODS: The new and old versions of the PPRS were compared 
across several dimensions: 1) price cuts; 2) price and proﬁt controls; 3) new initiatives; 
and 4) incentives. In particular, the recent introduction of “patient access schemes” 
(PASs) was examined. Recent risk-sharing agreements (Velcade and Lucentis) were 
presented as case studies. To provide an international perspective and cross-market 
comparison, the analysis also considered examples of risk-sharing schemes as used in 
